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Introduction: Degradation in fractal motor activity regulation (FMAR), a measure of
multiscale self-similarity of motor control, occurs in aging and accelerates with clini-
cal progression to Alzheimer’s disease (AD).Whether FMAR changes occur during the
pre-symptomatic phase of the disease in women andmen remains unknown.
Methods: FMAR was assessed in cognitively normal participants (n = 178) who
underwent 7 to 14 days of home actigraphy. Preclinical AD pathology was deter-
mined by amyloid imaging-Pittsburgh compound B (PiB) and cerebrospinal fluid (CSF)
phosphorylated-tau181 (p-tau) to amyloid beta 42 (Aβ42) ratio.
Results: Degradation in daytime FMAR was overall significantly associated with pre-
clinical amyloid plaque pathology via PiB+ imaging (beta coefficient β = 0.217, stan-
dard error [SE] = 0.101, P = .034) and increasing CSF tau181-Aβ42 ratio (β = 0.220,
SE = 0.084, P = .009). In subset analysis by sex, the effect sizes were significant in
women for PiB+ (β = 0.279, SE = 0.112, P = .015) and CSF (β = 0.245, SE = 0.094,
P= .011) but not inmen (both Ps> .05). These associations remained after inclusion of
daily activity level, apolipoprotein E ε4 carrier status, and rest/activity patterns.
Discussion:Changes in daytime FMAR fromactigraphy appear to be present inwomen
early in preclinical AD. This may be a combination of earlier pathology changes
in females reflected in daytime FMAR, and a relatively underpowered male group.
Further studies are warranted to test FMAR as an early noncognitive physiological
biomarker that precedes the onset of cognitive symptoms.
KEYWORDS
actigraphy, amyloid positron emission tomography imaging, amyloid plaque pathology, amyloid
beta 42, fractal regulation, interdaily stability, intradaily variability, phosphorylated tau, Pitts-
burgh compound B, preclinical Alzheimer’s disease, sex differences
1 INTRODUCTION
Alzheimer’s disease (AD) continues to lack early and readily obtained
biomarkers of risk in earlier life.1 There has been increasing interest in
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
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the role of continuousmonitoring ofmotor activity in free-living adults
in predicting cognitive decline.2,3 Recently, it was shown that the
self-similarity of actigraphy-derived motor activity fluctuations when
magnified across different time scales, known as fractal motor activity
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regulation (FMAR), is linked to AD; and alterations in FMAR coincided
with cognitive decline, accelerating during progression to mild cogni-
tive impairment (MCI), throughmild/moderate/severe dementia.4–6
In fact, complex temporal patterns including fractal patterns
have been observed in many physiological signals7–9 such as gait,10
mobility,11 motor function,12 and activity patterns,4,5 all of which have
been linked to AD and pathology.13–16 It has been accepted that fractal
patterns are generated by multiple such processes in an ongoing
feedback loop.7 In addition to AD diagnosis, perturbed daytime FMAR
has been associated with increased disability, frailty, and mortality in
the elderly.3,15,17,18 However, much of this evidence has either been
close to AD diagnosis3,19 or thereafter.6 The relationship between
daytime FMAR and early, preclinical AD pathology in cognitively
normal individuals is unknown.
In this study, we analyzed the relationship between daytime FMAR
and both imaging and cerebrospinal fluid (CSF)-derived amyloid and
tau AD biomarkers in cognitively normal participants who underwent
7 to 14 days of actigraphy in their home environment. We accounted
for apolipoprotein E (APOE) ε4 carrier status and examined potential




All participants were from the Washington University Knight
Alzheimer’s Disease Research Center (ADRC) in St. Louis, Missouri.
Inclusion criteria were age over 45 years, no cognitive impairment
(Clinical Dementia Rating score 0), and no abnormal movement of the
nondominant arm. Participants provided written, informed consent
for an add-on actigraphy study, described in detail elsewhere.16,21
We included 178 participants (mean age [standard deviation (SD)]
65.9 [8.3] years) who completed the actigraphy study, and had at
least one AD biomarker available through the ADRC. Participant
procedures were approved by the Washington University Human
Research Protection Office. This current analysis was approved by
the Partners Healthcare, Inc. Institutional Review Board and was part
of the Knight ADRC-approved project D1821 (Neuropathology for
disruptedmultiscale activity control in Alzheimer’s disease).
2.2 Biomarkers of AD pathology
Pittsburgh compound B (PiB) positron emission tomography (PET)
amyloid imaging was performed in 150 and cerebrospinal fluid (CSF)
was obtained in 149 participants (121 participants had both, whereas
57 had one AD biomarker only). An a priori cut-off value of total mean
cortical standard-uptake-value ratio > 1.42 as PiB positive (PiB+),
using the regional spread function technique; those ≤ 1.42 were
deemed PiB negative (PiB–).22 CSF was obtained via lumbar puncture
as previously described.23 Amyloid beta 42 (Aβ42) and phosphorylated
RESEARCH INCONTEXT
1. Systematic review: Recent studies indicate that frac-
tal motor activity regulation (FMAR) may be a novel
biomarker for Alzheimer’s disease (AD), particularly in
elderly subjects during the years prior to diagnosis. How-
ever, the relationship between FMAR degradation and
preclinical AD pathology in younger, cognitively normal
adults is unknown.
2. Interpretation: This study showed for the first time a
link between FMAR and AD via preclinical pathology in
women that was independent of age, race, education,
daily activity, and apolipoprotein E ε4 status.
3. Future directions: Future studies may aim to (1) repli-
cate the associations between FMAR and preclinical AD
pathology in larger samples of men; (2) determine what
mechanisms underlie these associations; (3) test the rela-
tionship between FMAR alterations and other types of
dementia; and (4) explore whether interventions can
modulate FMAR as a way to delay the onset of AD.
HIGHLIGHTS
1. Fractal motor activity regulation (FMAR) is associated
with preclinical Alzheimer’s disease (AD) pathology in
cognitively normal women.
2. The relationship is independent of age, physical activity,
rest-activity pattern fragmentation, and apolipoprotein E
ε4 carrier status.
3. FMARmay represent anovel biomarker forpreclinicalAD
pathology.
tau181 (p-tau) were measured by the ADRC Biomarker Core using
enzyme-linked immunosorbent assay (INNOTEST; Innogenetics).16
CSF p-tau—to–Aβ42 ratio was calculated as a sensitive and specific
biomarker for AD-related neurodegeneration given its specificity for
preclinical AD, and conversion to symptomatic AD.24 Consistent with
a recent study, all participants had biomarker data from 3 years before
to 0.5 years after actigraphy recording included in this study, and irre-
versibility of AD pathology was assumed.16 In summary, biomarkers of
preclinical AD pathology used in this studywere (1) PiB status (PiB+ or
PiB–) as a dichotomous variable, and (2) p-tau–to–Aβ42 ratio as a con-
tinuous variable.
2.3 Data collection and preprocessing
Motor activity was continuously monitored for 14 days using an acti-
graph monitor (Actiwatch2; Phillips-Respironics) worn on the non-
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F IGURE 1 Fractal motor activity regulationmeasurement. Representative motor activity recordings from actigraphy over one full
representative week for two participants, withΔα values in the 90th (A: in red) and 10th percentiles (B: in black) are shown. Gray shading indicates
7 PM to 11 AM data, which were excluded. C, F(n) is fitted using a power law, indicating a fractal structure in the fluctuations, and is plotted against
time on a log-log scale. F(n) is fitted separately in two regions: 1.25 to 90minutes, and 120 to 600minutes. The slopes of the lines in the two
regions are α1 and α2, respectively.Δα is the difference between the two slopes, α1 and α2; higherΔα is worse, indicating an inconsistency of fractal
motor activity regulation between the shorter and longer time scales
dominant wrist. Data were sampled at 32 Hz and integrated into 30-
second epochs. To ensure good signal quality, recordings were checked
using an established MATLAB GUI program (Ver. R2015a, the Math-
Works Inc.) 15,25,26 and quality issues such as (1) isolated spikes with
amplitude beyond 10 SD away from the individual global mean levels;
and (2) sequences of zeros with duration > 60 minutes during the day-
time (likely representing off-wrist periods) were identified andmarked
as gaps.27,28 Finally, each recording wasmanually inspected to confirm
quality control prior to FMAR assessment.
2.4 Fractal motor activity regulation
To assess FMAR, we investigated the temporal correlation property
of motor activity fluctuation at an array of timescales by perform-
ing detrended fluctuation analysis (DFA) with two-order polynomial
detrending.28,29 The DFA calculates the fluctuation amplitude, F(n), as
a function of time scale n. A power-law form of F(n), that is, F(n)∼nα,
indicates a fractal structure in the fluctuations (Figure 1). The temporal
correlation in the fluctuations can be quantified by the scaling expo-
nent, α, where 0.5 indicates no correlation in the fluctuations (“white
noise”), and > 0.5 indicates positive, whereas < 0.5 indicates negative
temporal correlations. Positive temporal correlation implies that adja-
cent values in time tend to have similar values (i.e., large values more
likely followed by large values), and negative temporal correlation sug-
gests that adjacent values in time are more likely different from each
other (i.e., large values more likely followed by small values). Mathe-
matically, the upper limit for α is 3 for the DFA using two-order poly-
nomial detrending (stronger correlations for larger values),27 but most
physiological outputs under healthy conditions have a value close to
1.0.28 This imitates the behavior of “pink” (1/f) noise, a signal/process
inwhich the power spectral density is inversely proportional to the sig-
nal frequency; it represents a delicate balance between total random-
ness (white noise) with no control and excessive regularity (periodic
signals), with too rigid a control (no response or flexibility). In fact, this
is one of the most common patterns in the output of healthy biological
systems,30 including the brain activity; recent evidence suggests that
pink noise can enhance slow-wave sleep (associatedwithmemory con-
solidation) in patients withMCI.31
FMAR degradation can be assessed from the changes in F(n) and α.
One typical change is decreases in α valueswith age (i.e., motor activity
fluctuations become more like white noise).3,7,32 However, the rate of
decrease appears to be disproportionate over two time scale regions
in AD and dementia with faster decline at time scales > 2 hours (up to
24 hours, α2) than < 90 minutes (α1); this leads to the deviation of F(n)
from a power-law form (a straight line) with α1 > α2.4–6,32 Therefore,
we used the difference, that is,Δα= α1-α2, to assess such degradation
in FMAR (Figure 1). Increased Δαwas previously observed to be more
strongly linkedwith neurodegeneration,32 particularly in the suprachi-
asmatic nucleus, and with cortical amyloid plaque burden, versus core
body temperature andmotor activity derived rest/activitymeasures.33
In addition, we focused on peak daytime activity data (i.e., 11 AM-7 PM)
to assess FMARchanges independentof thepotential effects of altered
sleep thatmay cause nocturnalmotor activity. Collectively, considering
an epoch length of 30 seconds and the decreased length of consecu-
tive data recordings due to the exclusion of nighttime period/gaps, we
quantified α1 in the range of 3 to 90minutes and α2 in the range of 2 to
8 hours.
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TABLE 1 Participant characteristics
Characteristic All (n= 178) PiB+ PiB– P
Mean (SD) or N (%) (n= 33) (n= 117)
Age, years 65.9 (8.3) 69.8 (5.4) 64.6 (8.6) .001
Sex, women 117 (66%) 20 (61%) 80 (68%) .44
Education, years 16.2 (2.4) 15.6 (2.5) 16.3 (2.4) .14
Race, non-Hispanic white 167 (94%) 32 (97%) 110 (94%) .68
APOE ε4 carrier 66 (37%) 18 (55%) 38 (32%) .02
log(p-tau–to–Aβ42)* NA –0.89 (0.26) –1.21 (0.18) <.001
Abbreviations: Aβ, amyloid beta; APOE, apolipoprotein E; PiB, Pittsburgh compound B; SD, standard deviation.
Notes: APOE ε4 carrier (1 or 2 alleles); log(pTau-to-Aβ42) cerebrospinal fluid phosphorylated Tau 181 (pTau) to amyloid-β-42 (Aβ42) ratio, log transformed for
non-normal distribution.
*121 participants with both PIB and log(pTau-to-Ab42) available.
2.5 Assessment of covariates
Agewas in years at start of actigraphy recording. Biological sex at birth,
race (non-HispanicWhite, Black, or other), education (years) were self-
reported. APOE ε4 genotype was dichotomized to carrier (one or two
alleles) versus noncarrier. Mean daily activity was estimated from the
extent of actigraphy accelerations in arbitrary units (a.u.).We also con-
sidered the following measures of rest/activity patterns using pub-
lished results and methodology from this cohort:16,34,35 (1) interdaily
stability (IS) of daily activity rhythm (similarity between days; higher
values indicatemore day-to-day stability);36 and (2) intradaily variabil-
ity (IV; how consolidated the rest/activity rhythms are). Low IV results
occur when there is a continuous period of high activity and a continu-
ousperiodofminimal activity during eachday; higher IV indicatesmore
fragmentation of the rest/activity pattern.35
2.6 Statistical analysis
We examined all continuous variables for normal distribution by visual
inspection of histograms and the Kolmogorov-Smirnov test. The p-
tau–to–Aβ42 ratio was log-transformed due to non-normal distribu-
tion. Comparisons between two groups (PiB+ and PiB– status) were
conducted using independent t tests for normally distributed contin-
uous variables, Mann-Whitney U tests if non-normally distributed, or
Chi-squared tests for categorical variables. Correlationswere assessed
with Pearson’s correlation.
We constructed multiple regression models with PiB status as a
dichotomous predictor, and separately with log (p-tau/Aβ42) as a con-
tinuous predictor, accounting for available covariates that may affect
both FMAR and preclinical AD pathology; these were entered step-
wise in the following order: our core model (Model A) included demo-
graphics (age, sex, education years, and ethnicity), Model B addition-
ally included mean daily activity level, Model C added APOE ε4 geno-
type, andModels D1 andD2 added two rest/activitymeasures one at a
time given their known collinearity. The effects of the time lag between
AD biomarker assessment and FMAR assessment on all associations
were explored, but were not significant. Therefore, the time lag was
not included as a covariate to preserve degrees of freedom. Related to
this, to assess clinical utility of FMAR (alongside age, sex, race, educa-
tion, daily activity, and APOE) in the prediction of AD biomarker sta-
tus, we also included further analysis examining the odds of prior PiB+
at the time of imaging, based on the upper half (≥ median) and lower
half (<median) ofΔα, assuming that AD pathologywas irreversible. All
tests were two-sided, with an α level of 0.05. Statistical analyses were
performed using JMP Pro (Ver. 14, SAS Institute).
3 RESULTS
3.1 Participant characteristics
Demographics and characteristics of participants are summarized in
Table 1. Overall, the participants were more likely to be female (66%,
n = 117), aged (mean [SD]) 65.9 [8.3] years, and have had 16.2 [2.4]
years of education (Table 1). Among the 150 participants with PiB
PET imaging, 22% (n = 33) were PiB+ and, compared to PiB– partici-
pants, they were older (69.8 [5.4] vs. 64.6 [8.6] years, P = .001), more
often APOE ε4 carriers (55% vs. 32%, P = 0.02), and with higher log(p-
tau/Aβ42) (–0.89 [0.26] vs. –1.21 [0.18], P < .001), in a subset of 121
with both markers available. Figure 1 shows motor activity recordings
over 1 week, and the corresponding FMAR (Δα) from two representa-
tive female participants at the same age (78 years), one PiB+ with Δα
in the 90th centile of the cohort, and one PiB–withΔα in the 10th cen-
tile. FMAR was normally distributed, with a median value of 0.10, and
ranged from –0.45 to+0.48 (Figure 2).
The effects of age, sex, daily activity level, and APOE ε4 genotype
on daytime FMAR are shown in Figure 3. With increasing age, there
was a trend toward increased Δα but this effect was not significant
(r=0.11, P= .13; Figure 3A). After adjusting for age, women had higher
Δα (0.10 vs. 0.04 in men, P = .016; Figure 3B). Daily activity level had
no significant effect onΔα (r= –0.08, P= .25; Figure 3C). There was no
significant difference inΔα between APOE ε4 carriers and non-carriers
(0.076 present vs. 0.074 absent, P= .88; Figure 3D).
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F IGURE 2 The distribution of the fractal motor activity regulation
Δαmetric. Themedian value of 0.10 is represented by the black dotted
line. Red line represents 10th centile whereas the blue dotted line
represents the 90th centile
3.2 AD biomarkers and FMAR (Δα)
Wecompared PiB+ participants (n= 33) to PiB– participants (n= 119)
to examine the effect of amyloid plaque pathology on FMAR. PiB+ par-
ticipants had significantly higher daytime Δα than PiB– participants in
our core multivariate model after accounting for the potential effects
of age, sex, education, and race (Figure 3E). The magnitude of this dif-
ference in Δα was 21.7% of the SD when “All” subjects were included
(Table 2, Model A: estimate = 0.217, standard error [SE] = 0.101,
P = .034). This relationship remained unchanged after including mean
daily activity level (Model B: estimate = 0.226, SE = 0.102, P = .028),
and APOE ε4 genotype (Model C: estimate = 0.223, SE = 0.105,
P = .035). After inclusion of individual rest/activity measures (IS and
IV), the associations between PiB status and FMAR remained signifi-
cant (Models D1-D2; Table 2). In further analysis, when a participant
had an assessed Δα in the upper half (≥0.10, median value in Figure 2),
there was significantly increased odds for prior PiB+ at the time of
imaging, compared to those in the lower half (odds ratio [OR] 3.32, 95%
confidence interval [CI] 1.33–8.30, P = .010); this was independent of
age, sex, education, race, daily activity, and APOE (see Table S1 in sup-
porting information).
We also examined CSF log(p-tau/Aβ42) as a continuous measure
of AD-specific pathological burden. There was a positive correlation
between log(p-tau/Aβ42) and daytime Δα for all participants with
available CSF biomarkers (Figure 3F). In our core model, every 1-SD
increase in log(p-tau/Aβ42) was associated with a 22.0% SD increase
in Δα (Table 2, Model A: estimate = 0.220, SE = 0.084, P = .009). This
relationship also remained unchanged after inclusion of daily activity
(Model B: estimate = 0.228, SE = 0.083, P = .007) and APOE geno-
type (Model C: estimate = 0.218, SE = 0.087, P = .013). Similarly, the
inclusion of IS/IV in Models D1-D2 did not affect the association. Full
model results for PiB status and log(p-tau/Aβ42) onΔα are summarized
in Tables S2-S3 in supporting information.
Given that we observed significantly higher Δα in women, a sub-
set analysis by sex was performed (Table 2). The associations of Δα
with AD pathology measures were significant in women for both PiB+
(β = 0.279, SE = 0.112, P = .015) and CSF log(p-tau/Aβ42) (β = 0.245,
SE = 0.094, P = .011), but not in men for either PiB+ (β = 0.187,
SE = 0.201, P = .357) or CSF log(p-tau/Aβ42) (β = 0.130, SE = 0.167,
P= .438).
4 DISCUSSION
This study identified for the first time an association between FMAR
and preclinical AD biomarkers that warrants further investigation and
validation. We found that changes in daytime FMAR (higher Δα) were
associated with preclinical AD pathology in healthy, cognitively nor-
mal adults, as measured by amyloid imaging (PiB status) or CSF p-
tau–to–Aβ42 ratio. These associations were significant after inclusion
of age, sex, education, race, mean daily activity, and APOE ε4 carrier
status. However, women had higher daytime FMAR degradation, and
appeared to drive the above associations. These findings suggest that
daytime FMAR imparts new information, particularly in women, about
AD pathogenesis at the early stage of the disease prior to the onset of
cognitive symptoms.
Fractal regulation has been used to characterize health status and
clinical outcome in many diseases,7 including the prediction of MCI
and AD dementia.4–6 We recently showed for the first time that FMAR
predicted incident clinical AD by 5 years on average.3 However, given
that preclinical AD pathology may develop more than 10 to 20 years
prior to symptomatic cognitive impairment,37,38 this is the first study
demonstrating an association between early preclinical AD pathology
and FMAR changes. Additionally, Δα significantly associated with CSF
p-tau–to–Aβ42 ratio, a continuous measure of AD-specific pathology,
suggesting that FMAR may be able to serve as a marker of preclinical
AD progression.
Interestingly, FMAR appeared to be more degraded in women than
men (P= .016, Figure3B). This is in keepingwith a prior study in healthy
subjects in which FMAR degradation appeared steeper in females,
starting as early as young adulthood between 30 and 40 years of
age.39 However, in an elderly community cohort (also predominantly
women, but≈20 years older than our cohort on average), FMARdegra-
dation was higher with age, but no difference in FMAR degradation
was observed between sexes.3,6 In this study, FMAR degradation also
trended higher with age, but was not significant. Thus, FMAR’s link to
sex may well be age dependent. Δα, as one of many accepted FMAR
measures,mayonly reflect anaspectof FMARchange that is influenced
by sex, but only in younger cohorts.
Most importantly, though results were significant for the whole
cohort, the associations between AD pathology and FMAR remained
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F IGURE 3 Effect of Alzheimer’s disease (AD) biomarkers and demographic characteristics on fractal motor activity regulation. All plots show
Δα on the y axis, with higher values indicatingmore degradation of fractal motor activity regulation. A, Increasing age in years (y) was
non-significantly associated with higherΔα. B,Women had higherΔα. C, Decreasedmean daily activity (in arbitrary units) was non-significantly
associated with higherΔα. Scatterplot shows linear regression line plus 95% confidence interval. D, There was no difference inΔα between APOE
ε4 carriers and non-carriers. E,Womenwith preclinical AD pathology, as defined by Pittsburgh compound B (PiB) positron emission tomography
(PET) positivity (PiB+), had higherΔα than participants whowere PiB negative (PiB–). F, Greater AD-specific pathological burden, as measured by
cerebrospinal fluid phosphorylated tau 181 (p-tau) to amyloid beta 42 (Aβ42) ratio [log (p-tau/Aβ42)], was significantly correlated with higherΔα
in women (orange triangles and solid line; r= 0.26, P= .011), but not in men (blue circles and dashed line; r= 0.10, P= .438). Box plots show
interquartile range (IQR) as boxes, median as center line, and 1.5 x IQR as whiskers. Outliers are represented as individual markers. P values
adjusted for age (B) or age, sex, education, and race (C-F)
significant only in females. The effect sizes forPiB+onFMARappeared
larger inwomen, but in formal testing, being femaledidnot significantly
augment the effects of amyloid plaque positivity on FMARdegradation
(data not shown). The makeup of the Washington University ADRC, in
which the female sample size was larger than the male sample (66%
women, Table 1), resulted in lower standard errors (narrower con-
fidence intervals) for women, and/or greater variability in men (Fig-
ure 3B), which may contribute to the sex differences for significance
thresholds being reached in our fully adjustedmodels. However, power
differences may not fully explain the significantly higher Δα in women
(0.10 vs. 0.04 in men, P = .016). The possibility for earlier AD pathol-
ogy changes in women is supported by the other findings showing that
women have higher prevalence of AD,40 faster cognitive decline41 and
differences in underlying AD pathology, on both neuroimaging42 and
CSF.43 Taken together, this warrants further work within larger sam-
ples to examine FMAR changes during middle age,1 as well as the tra-
jectory of FMARwith aging in both women and men using longitudinal
within-subject study designs.
Mechanistically, poor or impaired motor function, and low phys-
ical activity levels have all been linked to MCI, AD, and cognitive
GAO ET AL. 7 of 9
TABLE 2 Sex-specific preclinical AD amyloid plaque pathology and disease burden on fractal motor activity regulation
PiB+/PiB– log(p-tau/Aβ42)
β, SE All Female Male All Female Male
P value n= 150 n= 100 n= 50 n= 149 n= 93 n= 56
Model A 0.217, 0.101 0.279, 0.112 0.187, 0.201 0.220, 0.084 0.245, 0.094 0.130, 0.167
(core) 0.034 0.015 0.357 0.009 0.011 0.438
Model B 0.226, 0.102 0.280, 0.112 0.199, 0.207 0.228, 0.083 0.231, 0.094 0.236, 0.176
(+daily activity) 0.028 0.014 0.341 0.007 0.017 0.187
Model C 0.223, 0.105 0.272, 0.115 0.215, 0.217 0.218, 0.087 0.224, 0.100 0.240, 0.188
(+APOE ε4) 0.035 0.020 0.327 0.013 0.026 0.209
Model D1 0.225, 0.106 0.267, 0.116 0.197, 0.221 0.224, 0.089 0.224, 0.089 0.201, 0.105
(+IS) 0.036 0.024 0.378 0.013 0.013 0.309
Model D2 0.214, 0.106 0.287, 0.118 0.204, 0.214 0.201, 0.092 0.279, 0.106 0.208, 0.200
(+IV) 0.044 0.017 0.347 0.030 0.010 0.594
Notes: Effects of amyloid plaque pathology (PiB, Pittsburgh compound B status) and cerebrospinal fluid (CSF) AD-specific disease burden biomarker log(p-
tau/Aβ42) on fractal motor activity regulation (FMAR) in all subjects, and by sex. β represents change in Δα in standard deviations (SDs), alongside corre-
sponding standard errors (SE) and P values, for PiB+ compared to PiB–, or per each SD increase in log(p-tau/Aβ42). The core Model A included age, sex,
education, and ethnicity. Model B additionally included mean physical activity level. Model C additionally included APOE ε4 status. Models D1 and D2 addi-
tionally included for rest/activity measures IS interdaily stability, and IV intradaily variability.
decline.2,13,14,46,47 The current study showed a strong and consistent
association between preclinical AD pathology and FMAR, raising the
possibility that motor dysfunction and FMAR share common under-
lying pathophysiology (i.e., neurodegeneration). While activity level
is only one domain in the assessment of motor function, we did not
observe a strong association between FMAR and daily activity lev-
els. Motor function is multifaceted and likely only partially reflected
in FMAR. In addition, FMAR may involve the other physiological con-
trol systems that interact with themotor control system.48 Morework
is required to understand how FMAR reflects healthy motor function
beyond simply total activity levels.
Finally, there is increasing evidence that rest/activity patterns, a
proxy for underlying circadian regulation (the body’s daily rhythm and
control of physiological processes), is an early sign of AD preceding
the onset of cognitive symptoms.16,49,50 At the same time, our work
has shown that the maintenance of fractal activity patterns requires
intact circadian regulation.33,51 Given that higher IV, a measure of
rest/activity pattern fragmentation, was also positively correlated
with AD pathology in the same cohort,16 it is not surprising that FMAR
degradation trended toward a positive correlation with higher IV (Fig-
ure S1 in supporting information). However, the relationship between
FMAR and preclinical AD remained significant despite the inclusion
of IV in our final model. We would argue these results for FMAR
show consistency with prior circadian links to AD. Taken together,
we believe FMAR better encompasses physiological processes rel-
evant to cognitive decline than age alone, individual measures of
activity levels, rest/activity patterns, and even genetic predispo-
sition by revealing unique information in preclinical AD. Future
studies determining the neural circuitry for FMAR may shed light on
the neuroanatomical/neuropathological changes underlying these
findings.
Among the strengths of this study, to the best of our knowledge,
these are the first results incorporating fractal regulation and in vivo
AD biomarkers (both CSF and PiB PET imaging). The Knight ADRC
cohort is significant given thenatureof thedata collected,withdetailed
clinical and dementia assessments that ensure consistent phenotyp-
ing. Actigraphywas collected for 14 days, providing an excellent source
data for analyses, in combination with established FMAR analysis pro-
tocols. When we assume irreversibility of AD pathology, having an
assessed value forΔα greater than the 50th centile value in this cohort
was associated with more than 1-fold increased odds of being PiB+ at
the time of imaging, which was comparable to the odds of PiB+ from
being a APOE ε4 carrier versus a non-carrier (Table S1). The poten-
tial application of FMAR measures in screening people with a high
probability of AD pathology should be desirable because AD biomark-
ers such as amyloid and tau are expensive or invasive to obtain. To
improve upon its utility, future work should combine this unobtrusive
monitoring method in participants’ natural environment, with other
inexpensive/non-invasive clinicalmeasures; thismakes itmore feasible
to identify higher risk individuals at an earlier stage, who may then go
onto lumbar puncture or AD imaging.52–55
We acknowledge some limitations of our study. The cohort was
relatively homogeneous; therefore, we were unable to fully consider
race or ethnicity in our analyses. It is possible that changes in FMAR
occurred during up to 3-year’s lag between actigraphy recording and
AD biomarker measurement. However, assuming irreversibility of AD
pathology and the strength of association within the two separate
AD pathology measures, it seems probable that the time lag would
have biased our findings toward the null. It is also possible that the
observed relationships are caused by non-amyloid/tau pathologies in
the aged brain. In particular, sleep disordered breathing is common and
can influence amyloid burden,56 but was not assessed in this cohort.
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The relationship between FMARalterations and other types of demen-
tia has also not yet been explored. Ultimately, external validation and
replication are needed with more male subjects, in undiagnosed par-
ticipants with MCI, and accounting for comorbidities and medications
that may affect bothmotor activity patterns and AD pathology.
In summary, we found that FMAR degrades with preclinical AD
pathology, and that this effect was largely driven by female partici-
pants. The proposed FMAR measure is independent of age, APOE ε4
status, mean daily activity, and rest/activity patterns. These results
warrant further investigation to establish the potential of fractal
regulation as a passively obtained, non-cognitive and physiological
biomarker for AD. To improve the prediction/detection of AD demen-
tia, future studies may combine FMAR with other imaging and/or
behavioralmeasures and use advanced techniques ofmachine learning
to extract the best features or biomarkers for AD risk.
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